Dumas & Associates Law Firm L L C

Information may not be reliable

Zelnorm is a prescription medicine approved in July 2002 for short-term treatment of women with irritable bowel syndrome whose primary symptom is constipation. It was subsequently approved in August 2004 for treatment of chronic constipation for men and women under age 65.
The Food and Drug Administration (FDA) has requested that Novartis Pharmaceuticals Corporation of East Hanover, New Jersey, voluntarily discontinue marketing of Zelnorm (tegaserod) based on the recently identified finding of an increased risk of serious cardiovascular adverse events (heart problems) associated with use of the drug. Novartis has agreed to voluntarily suspend marketing of the drug in the United States.
Click this link to learn more information on Zelnorm

1261 Government Street • Baton Rouge, Louisiana 70802 • 800.219.2130 Toll Free • 225.383.4701 Office • 225.383.4719 Fax